- Home
- SAGE
as 05-30-2025 4:00pm EST
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 413.9M | IPO Year: | 2014 |
| Target Price: | $9.88 | AVG Volume (30 days): | 815.0K |
| Analyst Decision: | Hold | Number of Analysts: | 19 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.79 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.62 - $13.47 | Next Earning Date: | 04-29-2025 |
| Revenue: | $47,404,000 | Revenue Growth: | -47.94% |
| Revenue Growth (this year): | 103.73% | Revenue Growth (next year): | 41.15% |
Latest Sage Therapeutics Inc. News
SAGE Breaking Stock News: Dive into SAGE Ticker-Specific Updates for Smart Investing
Investopedia
a day ago
Ulta Stock Jumps as Beauty Product Spending Continues
GlobeNewswire
a day ago
Drone Light Show Market to Soar to $5 Billion by 2034, Fueled by 13% CAGR and Rising Demand for Innovative Entertainment | Exactitude Consultancy
GlobeNewswire
a day ago
Silicon Photonics Market Set to Surge to USD 13.9 Billion by 2034, Driven by 12.5% CAGR | Exactitude Consultancy
Benzinga
a day ago
Northrop Grumman Raises $1 Billion Via Debt
GlobeNewswire
a day ago
Spinosad Active Ingredient Market Set for Steady Growth, Driven by Sustainable Farming Trends | Exactitude Consultancy
Newsfile
a day ago
Max Resource Corp. Announces Participation in THE Mining Investment Event, Quebec City, June 3-5, 2025
GlobeNewswire
a day ago
TEN, Ltd. Announces Date for the First Quarter 2025 Results, Conference Call and Webcast
GlobeNewswire
a day ago
The York Water Company Files a Rate Request Based on $145 Million in Investment
Compare SAGE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SAGE Sage Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.